168 related articles for article (PubMed ID: 30816332)
1. PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion.
Müller TA; Pennisi S; Zwick A; Decker S; Klein C; Rister B; Rudorf A; Kissel S; Follo M; Wäsch R; Illert AL; Pfeifer D; Oostendorp R; Waskow C; Dierks C; Duyster J
Leukemia; 2019 May; 33(5):1296-1301. PubMed ID: 30816332
[No Abstract] [Full Text] [Related]
2. A role for the CXCR4-CXCL12 axis in the little skate, Leucoraja erinacea.
Hersh TA; Dimond AL; Ruth BA; Lupica NV; Bruce JC; Kelley JM; King BL; Lutton BV
Am J Physiol Regul Integr Comp Physiol; 2018 Aug; 315(2):R218-R229. PubMed ID: 29641231
[TBL] [Abstract][Full Text] [Related]
3. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.
Dar A; Schajnovitz A; Lapid K; Kalinkovich A; Itkin T; Ludin A; Kao WM; Battista M; Tesio M; Kollet O; Cohen NN; Margalit R; Buss EC; Baleux F; Oishi S; Fujii N; Larochelle A; Dunbar CE; Broxmeyer HE; Frenette PS; Lapidot T
Leukemia; 2011 Aug; 25(8):1286-1296. PubMed ID: 21494253
[TBL] [Abstract][Full Text] [Related]
4. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
[TBL] [Abstract][Full Text] [Related]
5. A novel CXCR4 antagonist for hematopoietic stem cell mobilization.
Fricker SP
Expert Opin Investig Drugs; 2008 Nov; 17(11):1749-60. PubMed ID: 18922110
[TBL] [Abstract][Full Text] [Related]
6. SDF-1/CXCR4 blockade to mobilize hematopoietic progenitor cells from the placenta.
Jing D; Alakel N; Bornhäuser M; Ehninger G; Ordemann R
Bone Marrow Transplant; 2010 Nov; 45(11):1661-2. PubMed ID: 20173795
[No Abstract] [Full Text] [Related]
7. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL; Rettig MP; Cashen AF
Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
[TBL] [Abstract][Full Text] [Related]
8. Mobilization as a preparative regimen for hematopoietic stem cell transplantation.
Chen J; Larochelle A; Fricker S; Bridger G; Dunbar CE; Abkowitz JL
Blood; 2006 May; 107(9):3764-71. PubMed ID: 16439683
[TBL] [Abstract][Full Text] [Related]
9. Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization.
Jørgensen AS; Daugvilaite V; De Filippo K; Berg C; Mavri M; Benned-Jensen T; Juzenaite G; Hjortø G; Rankin S; Våbenø J; Rosenkilde MM
Commun Biol; 2021 May; 4(1):569. PubMed ID: 33980979
[TBL] [Abstract][Full Text] [Related]
10. AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
Fearon DT; Janowitz T
Br J Cancer; 2021 Jul; 125(2):149-151. PubMed ID: 33772153
[TBL] [Abstract][Full Text] [Related]
11. Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model.
Goodrich AD; Varain NM; Jeanblanc CM; Colon DM; Kim J; Zanjani ED; Hematti P
Cytotherapy; 2014 Sep; 16(9):1280-93. PubMed ID: 25108653
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier.
Thakar MS; Santos EB; Fricker S; Bridger G; Storb R; Sandmaier BM
Blood; 2010 Jan; 115(4):916-7. PubMed ID: 20110438
[No Abstract] [Full Text] [Related]
13. No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice.
Choi E; Branch C; Cui MH; Yazdanbakhsh K; Mohandas N; Billett HH; Shi PA
Blood Cells Mol Dis; 2016 Mar; 57():67-70. PubMed ID: 26852658
[TBL] [Abstract][Full Text] [Related]
14. Successful and safe stem cell mobilization using plerixafor in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Caocci G; Ledda A; Floris R; Vacca A; Arras M; Greco M; Sanna M; La Nasa G
Leuk Lymphoma; 2014 Feb; 55(2):462-3. PubMed ID: 23713454
[No Abstract] [Full Text] [Related]
15. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S
Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
[TBL] [Abstract][Full Text] [Related]
16. Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.
Paganessi LA; Walker AL; Tan LL; Holmes I; Rich E; Fung HC; Christopherson KW
Exp Hematol; 2011 Mar; 39(3):384-90. PubMed ID: 21168468
[TBL] [Abstract][Full Text] [Related]
17. Optimizing stem cell collection through CXCR4 antagonists.
Mahaseth H; Kaufman J
Front Biosci (Schol Ed); 2012 Jan; 4(2):611-9. PubMed ID: 22202080
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice.
Juarez JG; Harun N; Thien M; Welschinger R; Baraz R; Pena AD; Pitson SM; Rettig M; DiPersio JF; Bradstock KF; Bendall LJ
Blood; 2012 Jan; 119(3):707-16. PubMed ID: 22049516
[TBL] [Abstract][Full Text] [Related]
19. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.
Pusic I; DiPersio JF
Curr Opin Hematol; 2010 Jul; 17(4):319-26. PubMed ID: 20473162
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD69 therapy induces rapid mobilization and high proliferation of HSPCs through S1P and mTOR.
Notario L; Alari-Pahissa E; Albentosa A; Leiva M; Sabio G; Lauzurica P
Leukemia; 2018 Jun; 32(6):1445-1457. PubMed ID: 29483712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
